Follows adults with atrial fibrillation treated with the PulseSelect PFA System
Follows adults with atrial fibrillation who receive the PulseSelect PFA System.
Plain-language title generated from the registry record
Registry title: PulseSelect™ PFA Global Registry
Key facts
- Where
- Córdoba, Málaga, and Salamanca, SpainSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with atrial fibrillation who are planned to have a procedure with the PulseSelect PFA System.
- Age
- 18 years or older, or the minimum age set by local regulations.
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with atrial fibrillation (AF).
Main reasons for not taking part
- Being enrolled in another study that the global study manager has not approved for joint enrolment.
- Meeting exclusion criteria set by local law.
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario Reina SofiaCórdoba, SpainNo longer taking part
- H. Univ. Virgen de la Victoria - MalagaMálaga, SpainNo longer taking part
- Complejo Asistencial Universitario de SalamancaSalamanca, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Medtronic Cardiac Ablation Solutions
- Trial code
- NCT06393920
- Record updated
- 16 October 2026
- Original description
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.Read full original descriptionShow less
PulseSelect PFA Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.
Inclusion: Subject is ≥ 18 years of age or minimum age as required by local regulations; Subject has been diagnosed with atrial fibrillation (AF); Planned procedure using commercially available PulseSelect™ PFA System; Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.
Exclusion: Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager; Subject with exclusion criteria required by local law.